Your browser is no longer supported. Please, upgrade your browser.
EGRX [NASD]
Eagle Pharmaceuticals, Inc.
Index- P/E38.56 EPS (ttm)1.36 Insider Own0.20% Shs Outstand13.11M Perf Week-3.84%
Market Cap695.46M Forward P/E9.25 EPS next Y5.65 Insider Trans0.00% Shs Float11.45M Perf Month-3.22%
Income18.30M PEG14.28 EPS next Q0.83 Inst Own95.20% Short Float6.91% Perf Quarter9.99%
Sales189.20M P/S3.68 EPS this Y-14.00% Inst Trans-0.01% Short Ratio7.94 Perf Half Y27.60%
Book/sh14.86 P/B3.52 EPS next Y87.27% ROA7.10% Target Price48.50 Perf Year10.11%
Cash/sh8.17 P/C6.40 EPS next 5Y2.70% ROE9.80% 52W Range36.48 - 58.25 Perf YTD12.28%
Dividend- P/FCF15.84 EPS past 5Y40.60% ROI10.20% 52W High-10.23% Beta0.73
Dividend %- Quick Ratio3.70 Sales past 5Y23.20% Gross Margin75.60% 52W Low43.34% ATR1.73
Employees106 Current Ratio3.90 Sales Q/Q14.80% Oper. Margin17.00% RSI (14)43.03 Volatility2.50% 3.25%
OptionableYes Debt/Eq0.15 EPS Q/Q- Profit Margin9.70% Rel Volume0.79 Prev Close51.72
ShortableYes LT Debt/Eq0.11 EarningsAug 09 BMO Payout0.00% Avg Volume99.58K Price52.29
Recom2.30 SMA20-4.98% SMA50-0.01% SMA20012.96% Volume78,650 Change1.10%
Apr-07-21Resumed RBC Capital Mkts Outperform $52
Nov-01-18Downgrade Cantor Fitzgerald Overweight → Neutral
Oct-31-18Downgrade Piper Jaffray Overweight → Neutral
Mar-21-18Reiterated Mizuho Underperform $37 → $40
Nov-09-17Reiterated RBC Capital Mkts Outperform $81 → $75
Sep-06-17Reiterated Mizuho Underperform $40 → $37
Jul-27-17Reiterated RBC Capital Mkts Outperform $94 → $81
Jul-27-17Reiterated Mizuho Underperform $57 → $40
May-09-17Reiterated RBC Capital Mkts Outperform $86 → $94
Jan-09-17Downgrade Mizuho Neutral → Underperform $78 → $64
Nov-16-16Downgrade Mizuho Buy → Neutral $78
Nov-03-16Upgrade Mizuho Neutral → Buy $62 → $78
Nov-03-16Reiterated RBC Capital Mkts Outperform $80 → $93
Oct-26-16Reiterated Mizuho Buy $65 → $62
Aug-16-16Reiterated Mizuho Neutral $47 → $65
Jun-20-16Downgrade Mizuho Buy → Neutral $66 → $47
May-10-16Reiterated RBC Capital Mkts Outperform $94 → $78
Mar-18-16Reiterated Mizuho Buy $81 → $71
Feb-26-16Reiterated Mizuho Buy $112 → $81
Dec-09-15Initiated Mizuho Buy $112
Sep-22-21 08:43AM  
Sep-07-21 06:50AM  
Sep-01-21 05:00PM  
09:41AM  
Aug-31-21 12:33PM  
12:05PM  
11:45AM  
06:50AM  
Aug-25-21 06:50AM  
Aug-09-21 04:30PM  
08:05AM  
06:50AM  
06:45AM  
Aug-02-21 03:01PM  
Jul-29-21 03:32PM  
Jul-28-21 04:30PM  
Jul-14-21 02:28AM  
Jun-24-21 06:50AM  
Jun-18-21 10:47AM  
Jun-17-21 06:50AM  
Jun-11-21 12:08PM  
May-30-21 04:06AM  
May-26-21 05:00PM  
May-14-21 05:54PM  
May-11-21 05:00PM  
May-10-21 11:30AM  
08:05AM  
06:50AM  
06:45AM  
06:45AM  
May-03-21 03:01PM  
06:50AM  
Apr-30-21 06:50AM  
Apr-29-21 04:30PM  
07:05AM  
Apr-22-21 12:28PM  
Apr-15-21 03:22AM  
Mar-15-21 04:08PM  
Mar-03-21 12:23AM  
Mar-02-21 02:00PM  
08:15AM  
06:50AM  
06:30AM  
Mar-01-21 10:15AM  
Feb-22-21 04:30PM  
Feb-02-21 07:45AM  
06:50AM  
Feb-01-21 06:50AM  
Jan-11-21 06:50AM  
Jan-04-21 04:30PM  
Jan-03-21 02:45AM  
Dec-15-20 07:27PM  
Nov-23-20 06:50AM  
Nov-04-20 06:10AM  
Nov-02-20 12:30PM  
08:24AM  
08:05AM  
06:47AM  
06:45AM  
Oct-26-20 04:30PM  
Oct-15-20 09:20AM  
08:19AM  
Sep-25-20 02:13PM  
Sep-24-20 11:30AM  
11:30AM  
06:50AM  
Sep-23-20 06:50AM  
Sep-09-20 11:07AM  
Sep-08-20 06:50AM  
Aug-19-20 06:50AM  
Aug-10-20 01:30PM  
08:15AM  
07:06AM  
06:50AM  
Aug-03-20 04:30PM  
Jul-31-20 03:56PM  
Jul-17-20 11:47AM  
Jul-09-20 12:00PM  
Jun-27-20 09:28PM  
Jun-10-20 04:08PM  
May-26-20 04:30PM  
May-22-20 04:05PM  
May-14-20 11:50AM  
May-12-20 04:30PM  
May-11-20 12:30PM  
08:35AM  
08:14AM  
07:22AM  
06:50AM  
May-08-20 08:41AM  
May-07-20 06:07AM  
May-04-20 06:50AM  
Apr-29-20 04:30PM  
Apr-28-20 12:33PM  
06:50AM  
Apr-16-20 05:24PM  
06:50AM  
Apr-11-20 09:25AM  
Mar-30-20 06:50AM  
Mar-24-20 02:20AM  
Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RATOFF STEVEN BDirectorApr 08Option Exercise7.337,02051,43327,364Apr 12 04:38 PM
Tarriff ScottCEOApr 01Option Exercise8.7831,201273,9451,561,184Apr 05 04:54 PM